MA31500B1 - Composes chimiques - Google Patents

Composes chimiques

Info

Publication number
MA31500B1
MA31500B1 MA32473A MA32473A MA31500B1 MA 31500 B1 MA31500 B1 MA 31500B1 MA 32473 A MA32473 A MA 32473A MA 32473 A MA32473 A MA 32473A MA 31500 B1 MA31500 B1 MA 31500B1
Authority
MA
Morocco
Prior art keywords
chemical compounds
compounds
present
methods
preparation
Prior art date
Application number
MA32473A
Other languages
Arabic (ar)
English (en)
Inventor
Andrew James Peat
Paul Richard Sebahar
Michael Youngman
Pek Yoke Chong
Huichang Zhang
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA31500B1 publication Critical patent/MA31500B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés qui sont des inhibiteurs non nucléosidiques de la transcriptase inverse, et des procédés pour leur préparation et leur utilisation. De manière spécifique, la présente invention comprend des procédés d'utilisation de tels composés dans le traitement de l'infection par le virus d'immunodéficience humaine.
MA32473A 2007-06-06 2010-01-04 Composes chimiques MA31500B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94226607P 2007-06-06 2007-06-06
PCT/US2008/065865 WO2008154271A1 (fr) 2007-06-06 2008-06-05 Composés chimiques

Publications (1)

Publication Number Publication Date
MA31500B1 true MA31500B1 (fr) 2010-07-01

Family

ID=40130130

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32473A MA31500B1 (fr) 2007-06-06 2010-01-04 Composes chimiques

Country Status (25)

Country Link
US (1) US8304419B2 (fr)
EP (1) EP2166856A4 (fr)
JP (1) JP2010529965A (fr)
KR (1) KR20100039301A (fr)
CN (1) CN101790313A (fr)
AR (1) AR066909A1 (fr)
AU (1) AU2008261977A1 (fr)
BR (1) BRPI0812738A2 (fr)
CA (1) CA2694871A1 (fr)
CL (1) CL2008001631A1 (fr)
CO (1) CO6251246A2 (fr)
CR (1) CR11196A (fr)
DO (1) DOP2009000266A (fr)
EA (1) EA017141B1 (fr)
IL (1) IL202217A0 (fr)
MA (1) MA31500B1 (fr)
MX (1) MX2009013349A (fr)
NZ (1) NZ581409A (fr)
PE (1) PE20090330A1 (fr)
SG (1) SG182162A1 (fr)
TW (1) TW200901969A (fr)
UA (1) UA98784C2 (fr)
UY (1) UY31132A1 (fr)
WO (1) WO2008154271A1 (fr)
ZA (1) ZA200908604B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505834A (ja) * 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド系逆転写酵素阻害剤
WO2010075376A2 (fr) * 2008-12-23 2010-07-01 Abbott Laboratories Composés antiviraux
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
CA2770023A1 (fr) 2009-08-06 2011-02-10 Neuraltus Pharmaceuticals, Inc. Traitement de troubles associes aux macrophages
JP5851998B2 (ja) * 2009-10-27 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺虫剤および殺ダニ剤としてのハロアルキル置換アミド
CN110483499A (zh) 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
KR101732212B1 (ko) * 2010-03-18 2017-05-02 재단법인 한국파스퇴르연구소 항감염성 화합물
CA2797872A1 (fr) * 2010-05-21 2011-11-24 Gilead Sciences, Inc. Inhibiteurs des virus flaviviridae heterocycliques
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2511263A1 (fr) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Composés de pyrrolo sulfonamide pour la modulation d'activité de récepteur-gamma orphelin (gamme ROR, NR1F3) associée au RAR de récepteur nucléaire orphelin et pour le traitement des maladies inflammatoires et de maladies auto-immunes chroniques
JP2015512431A (ja) 2012-04-04 2015-04-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｇｐｂａｒ１モジュレーターとしての１，２−ピリダジン、１，６−ピリダジン又はピリミジン−ベンズアミド誘導体
US9890119B2 (en) 2013-02-27 2018-02-13 Shionogi & Co., Ltd. Indole and azaindole derivative having AMPK-activating activity
JO3603B1 (ar) * 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
BR112017028318B1 (pt) * 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
EP3328382A4 (fr) 2015-09-17 2018-12-19 Marvin J. Miller Composés hétérocycliques contenant de la benzylamine et compositions utiles contre une infection mycobactérienne
MX2018015656A (es) 2016-06-16 2019-03-14 Janssen Sciences Ireland Unlimited Co Compuestos heterociclicos como antibacterianos.
EP3535242B1 (fr) 2016-10-20 2024-01-24 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Inhibiteurs d'adn primase et gyrase
WO2018158280A1 (fr) 2017-03-01 2018-09-07 Janssen Sciences Ireland Uc Polythérapie
CN109748927A (zh) * 2017-11-03 2019-05-14 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
WO2019168164A1 (fr) * 2018-03-02 2019-09-06 国立大学法人大阪大学 Molécule pour la conception de protéines et/ou de peptides
US11370758B2 (en) * 2018-03-23 2022-06-28 Cmg Pharmaceutical Co., Ltd. IDO-TDO dual inhibitor and related methods of use
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
WO2020072580A1 (fr) 2018-10-02 2020-04-09 Disc Medicine, Inc. Inhibiteurs de matriptase 2 et leurs utilisations
US10959987B2 (en) 2019-04-15 2021-03-30 King Abdulaziz University Imidazole-based compounds as hepatitis C virus inhibitors
KR102051783B1 (ko) * 2019-09-02 2019-12-03 부산대학교 산학협력단 3,10-이치환 벤조풀벤 유도체의 신규 합성방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716446D0 (en) * 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
DE10161765A1 (de) * 2001-12-15 2003-07-03 Bayer Cropscience Gmbh Substituierte Phenylderivate
NZ542304A (en) * 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
AU2004269930B2 (en) * 2003-09-11 2011-08-04 Tibotec Pharmaceuticals Ltd. Entry inhibitors of the HIV virus
WO2005026114A1 (fr) * 2003-09-17 2005-03-24 Pfizer Inc. Inhibiteurs de la protease du vih, compositions les contenant et leurs utilisations pharmaceutiques
US20070082907A1 (en) * 2003-11-25 2007-04-12 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
ES2333802T3 (es) * 2004-04-23 2010-03-01 F. Hoffmann-La Roche Ag Inhibidores no nucleicos de transcriptasa inversa.
US20060004197A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
US20060025480A1 (en) * 2004-08-02 2006-02-02 Boehringer Ingelheim International Gmbh Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US7606430B2 (en) * 2005-08-30 2009-10-20 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method utilizing a multiple dictionary compression method for FPD
CN101679294B (zh) * 2007-05-30 2012-08-08 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂

Also Published As

Publication number Publication date
TW200901969A (en) 2009-01-16
CL2008001631A1 (es) 2009-01-02
SG182162A1 (en) 2012-07-30
IL202217A0 (en) 2010-06-16
UY31132A1 (es) 2009-03-31
EA200901490A1 (ru) 2010-06-30
PE20090330A1 (es) 2009-04-30
CN101790313A (zh) 2010-07-28
DOP2009000266A (es) 2010-02-15
US8304419B2 (en) 2012-11-06
CA2694871A1 (fr) 2008-12-18
UA98784C2 (ru) 2012-06-25
JP2010529965A (ja) 2010-09-02
AU2008261977A1 (en) 2008-12-18
EA017141B1 (ru) 2012-10-30
NZ581409A (en) 2012-03-30
KR20100039301A (ko) 2010-04-15
WO2008154271A1 (fr) 2008-12-18
EP2166856A4 (fr) 2012-05-30
ZA200908604B (en) 2011-02-23
CO6251246A2 (es) 2011-02-21
CR11196A (es) 2010-03-08
US20100216746A1 (en) 2010-08-26
BRPI0812738A2 (pt) 2014-09-30
MX2009013349A (es) 2010-01-20
AR066909A1 (es) 2009-09-23
EP2166856A1 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
MA31500B1 (fr) Composes chimiques
MA34002B1 (fr) Thérapie antivirale
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA31183B1 (fr) Inhibiteurs de mek
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34474B1 (fr) Agonistes de gpr40
MA33449B1 (fr) Antigènes recombinants du vrs
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA33279B1 (fr) Compositions et procédés pour l'augmentation de la croissance des muscles
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA34308B1 (fr) Triazolopyridines substituées
MA31256B1 (fr) Nouveaux anticorps humains anti-r7v et leurs utilisations
MY186986A (en) Compositions and methods of use of phorbol esters
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
ATE555108T1 (de) Polyamide zur behandlung des menschlichen papilloma-virus